Compare Abeona Therapeutics Inc (ABEO) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Fox Corp Class A — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Fox Corp Class A trades at $62.43 (market cap $25.05B). The key difference: Fox Corp Class A is far larger — about 59× Abeona Therapeutics Inc's market cap, and Fox Corp Class A pays a 0.91% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FOXA | |
|---|---|---|
Market Cap | $424.33M | $25.05B |
Sector | Health | Media |
52-Week High | $7.45 | $76.11 |
52-Week Low | $4.17 | $48.79 |
Enterprise Value | $279.23M | $28.41B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
FOXA trades at $64.03, up 3.63% on strong Q4 2026 earnings beats driven by World Cup advertising and Tubi streaming growth. The stock shows bullish technical momentum with a consensus price target of $65.33, supported by a 50% buy rating from analysts. Revenue grew to $16.30B in 2025, with net income margin expanding to 13.88%, though 2026 projections indicate moderation.
Outlook remains positive with digital ad momentum and strategic initiatives, but risks include sports cost pressures and cyclical advertising dependence. The current valuation at a P/E of 16.52 appears reasonable relative to earnings growth, offering potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
